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Noncontingent and Response-Contingent Intravenous
Ethanol Attenuates the Effect of Naltrexone on
Hypothalamic-Pituitary-Adrenal Activity in Rhesus
Monkeys
Keith L. Williams, Jillian H. Broadbear, and James H. Woods
Background: The mechanism by which the opioid antagonist naltrexone suppresses overconsumption of
ethanol is unclear. Oral ethanol consumption in humans increases hypothalamic-pituitary-adrenal (HPA)
activity, and recent studies suggest that naltrexone may reduce ethanol consumption by modifying the
HPA-stimulating effects of ethanol. The purpose of this study was to measure in rhesus monkeys the effects
of ethanol and naltrexone, alone and in combination, on plasma levels of adrenocorticotropin hormone
(ACTH).
Methods: Nine adult male and female rhesus monkeys with chronic, indwelling intravenous catheters
were maintained on tethers that allowed ethanol delivery and blood sampling. In one study, the monkeys
received intramuscular injections of saline or 0.32 mg/kg naltrexone followed by noncontingent intravenous
bolus infusions of saline or 0.3 to 1.8 g/kg ethanol. In a second study, other monkeys were given intramus-
cular injections of saline or 0.01 to 0.3 mg/kg naltrexone and subsequently responded on levers to receive
intravenous saline or ethanol 0.03 g/kg per injection.
Results: Ethanol, delivered either response contingently or noncontingently, did not produce systematic
changes in ACTH plasma levels. Naltrexone alone produced increases in plasma ACTH that were atten-
uated by the subsequent administration of noncontingent or response-contingent ethanol. Naltrexone also
produced dose-dependent reductions in intravenous ethanol self-administration. Linear regression analysis
indicated that ethanol intake was negatively correlated with the plasma levels of ACTH over time.
Conclusions: The route of administration may modulate ethanol’s effects on HPA activity. Ethanol may
attenuate naltrexone’s effect on the HPA axis by impairing HPA axis sensitivity to other stimuli. The
negative correlation between ethanol intake and ACTH levels supports the notion that naltrexone’s effect
of increasing HPA axis activity may be related to its ability to suppress ethanol consumption.
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ADMINISTRATION OF INTRAPERITONEAL injec-tions of ethanol in rodents or oral ethanol in humans
produces increases in plasma levels of adrenocorticotropin
hormone (ACTH) and corticosterone or cortisol, presum-
ably by activating the hypothalamic-pituitary-adrenal
(HPA) axis (Inder et al., 1995; McCaul et al., 2001; Men-
delson and Stein, 1966; Merry and Marks, 1969; Rivier,
1996). Naltrexone, which is effective in suppressing ethanol
consumption in heavy drinkers and alcoholics, also in-
creases plasma ACTH and cortisol levels in most studies in
humans (e.g., Farren et al., 1999; Mendelson et al., 1986;
Wand et al., 2001). Some investigators have suggested that
the HPA response to ethanol may be the basis for the
reinforcing effects of ethanol and also the basis for the
ability of naltrexone to decrease ethanol consumption (Mc-
Caul et al., 2001). However, there is a lack of agreement on
how naltrexone and ethanol interact on the HPA axis in
human subjects. McCaul et al. (2001) found that naltrexone
alone had no effect on ACTH or cortisol levels but that it
decreased the HPA-stimulating effects of a large (1.0 g/kg)
dose of oral ethanol in heavy drinkers. These investigators
suggested that “This [naltrexone-induced] dampening of
hormonal responses may contribute to the therapeutic ef-
fectiveness of naltrexone for reducing alcohol liking. . .” (p.
537). O’Malley et al. (2002), conversely, observed that
plasma levels of ACTH and cortisol were increased in
alcohol-dependent subjects who were drinking ethanol af-
ter chronic naltrexone administration, but not in subjects
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who were drinking ethanol in the absence of naltrexone.
The higher levels of ACTH in the naltrexone-treated,
ethanol-consuming subjects were associated with a de-
creased urge to drink and decreased ethanol consumption.
The researchers hypothesized that “naltrexone may reduce
drinking via suppressing craving for alcohol and that this
effect may be related in part to naltrexone’s ability to
activate the hypothalamo-pituitary-adrenocortical axis” (p.
19). In both of these studies, naltrexone was given orally for
6 or 8 days before ethanol was consumed, but in the Mc-
Caul et al. study, three drinks were assigned to be drunk
over a 15-min period. In the O’Malley et al. study, subjects
could choose whether or not to drink four alcoholic drinks
per hour for 2 hr or to accept $3 for each drink they did not
consume. It is therefore possible that different HPA re-
sponses to ethanol in combination with naltrexone result
when subjects have greater control over their ethanol
intake.
Although HPA activity increases in response to intra-
peritoneal injections of ethanol in rodents and in response
to oral ethanol consumption in humans, there is no evi-
dence that ethanol increases HPA activity in rhesus mon-
keys. In this study, ACTH levels were measured over time
after noncontingent or response-contingent intravenous
ethanol administration in rhesus monkeys to determine
whether ethanol increases stress hormone levels in mon-
keys, as it seems to do in rats and in most studies in
humans. The effects of intramuscular naltrexone on ACTH
levels were also measured over time. In addition, the ability
of naltrexone to modify intravenous ethanol intake and the
effect on ACTH levels of the combination of naltrexone
and either response-contingent or noncontingent ethanol
were determined.
METHODS
Subjects
Six adult male and three adult female rhesus monkeys (Macaca mu-
latta) weighing 6.4 to 13.7 kg were used. The monkeys received food and
water ad libitum and were treated according to the Guide for the Care and
Use of Laboratory Animals (National Research Council, 1996). All mon-
keys had intact adrenal glands and gonads.
Apparatus
The monkeys were housed individually in stainless-steel cages measur-
ing 83.3  76.2  91.4 cm (Bryan Research Equipment Corp., Bryan, TX).
The monkeys wore a Teflon mesh jacket (Lomir, Malone, NY) that was
attached to the back of the cage via a flexible stainless-steel tether. After
habituation to the cage and restraint device, the monkeys received an
indwelling silastic catheter that was inserted into a femoral vein. Catheters
were inserted during aseptic surgery with 10 mg/kg ketamine and 2 mg/kg
xylazine anesthesia. After placement in the vein, the catheter was guided
subcutaneously to the midscapular region, where it exited the monkey.
The catheter was enclosed in the tether until it exited the back of the cage,
where it was joined to additional silicone tubing. The silicone tubing was
attached to a filter (Gilman Scientific, Ann Arbor, MI) and connected to
an infusion pump (model MHRK55, Watson-Marlow Co., Falmouth,
UK). This apparatus allowed the experimenter to draw blood from and
infuse drugs to a monkey that was awake and able to move with minimal
restraint. The apparatus and surgery procedures are described in detail
elsewhere (e.g., Winger et al., 1975).
Procedure
Noncontingent Ethanol Administration. The four monkeys, two males
and two females, participating in this experiment had histories of oral
ethanol self-administration. Ethanol self-administration had ceased ap-
proximately 1.5 years before this experiment. The monkeys also partici-
pated in experiments examining the HPA response to intramuscular in-
jections of opioid antagonists (Williams et al., 2003). Approximately 6
weeks separated the antagonist injections of that study and the manipu-
lations of this experiment. They were randomized to receive either saline
or ethanol at doses of 0.3, 1, and 1.8 g/kg. Each dose was given twice, with
1 week between doses. Ethanol was infused at concentrations of 4% (0.3
g/kg), 13% (1 g/kg), and 25% (1.8 g/kg). These ethanol concentrations
were chosen so that the fluid volume infused would be constant across the
different doses. The volume varied for each animal on the basis of the
volume required to deliver the highest ethanol dose. Although the pumps
were set to infuse fluid at 12 ml/min, an infusion rate of 6 ml/min was
achieved by turning the pump on for 30 sec and off for 30 sec.
Initial blood samples were drawn at 9:30 AM (30 min in the figures)
and again at 9:45 AM. Ethanol infusions began at 9:55 AM (5 min) and
lasted for 8 to 9 min for the smallest monkey and 17 to 18 min for the
largest monkey. Blood sampling continued every 15 min for 1 hr after the
ethanol infusion and every 30 min for the next 2 hr.
After completing the previous manipulations, the monkeys received
intramuscular injections of 0.32 mg/kg naltrexone just before the second
blood sample (15 min), after which either saline or 1.8 g/kg ethanol was
infused. The monkeys experienced each condition twice, with 1 wk be-
tween conditions. Condition order was arranged so that one male and one
female were exposed to naltrexone/saline and then naltrexone/ethanol; the
order was reversed for the remaining monkeys.
Approximately 2 ml of blood was drawn at 10 time points over the
course of the day. Two blood samples were taken before the saline or
ethanol infusion (30 min and 15 min). After the infusion, samples were
taken every 15 min for the first hour (15, 30, 45, and 60 min) and then
every 30 min until 185 min after the initiation of the ethanol infusion.
Response-Contingent Ethanol Administration. The five monkeys, four
males and one female, used in this experiment were different from those
subjects used for noncontingent ethanol administration. Their cages were
equipped with a lever panel on the right side of the cage that had two
response levers located beneath three stimulus lights. The red light on the
right signaled drug availability. The green center light was illuminated for
the duration of the drug infusion. The third light was not used.
The experiments were controlled by Med Associates software (St.
Albans, VT) that was installed on computers in an adjacent room. Self-
administration periods occurred twice daily; one began at 10:00 AM, and
the second began at 4:00 PM. Each period consisted of four 25-min
response components, with each component separated by a 10-min time-
out component (total session time, 130 min). Blood samples were taken
during the time-out components. During the response component, drug
injections were delivered on a fixed-ratio 30 schedule of reinforcement.
Because ethanol was delivered at 30% w/v, large subjects required large
fluid volumes and pump durations up to approximately 50 sec. Each
injection was followed by a 60-sec time out. Responding during the time
between components and the postinjection time out had no consequences.
Self-administration training took place several months before this
study. The monkeys were typically trained to lever-press for 0.1 mg/kg per
injection of cocaine on a fixed-ratio 1 schedule. The response requirement
was then increased to 20 or 30, depending up the experiment. The
monkeys self-administered a variety of psychoactive drugs while partici-
pating in different experiments. During the weeks before ethanol self-
administration, the monkeys had access to 0.1 mg/kg per injection of
methohexital. Ethanol self-administration was established by using 0.03
g/kg per injection of ethanol delivered with 30% w/v ethanol. Occasionally,
saline was substituted for ethanol in the self-administration reservoir.
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The experimental conditions in this study included access to 0.03 g/kg
per injection of ethanol 30 min after receiving an intramuscular injection
of saline or 0.01, 0.03, 0.1, or 0.3 mg/kg naltrexone. Other conditions
included access to intravenous saline 30 min after receiving an intramus-
cular injection of saline or 0.3 mg/kg naltrexone. The order was random-
ized for each monkey, with the exception that the last condition experi-
enced for all monkeys was access to response-contingent saline infusions
after receiving an injection of 0.3 mg/kg naltrexone. Blood samples were
drawn once per week, and naltrexone was given no more than once per
week. Naltrexone testing and blood sampling occurred during the morning
self-administration period.
Approximately 2 ml of blood was drawn before, during, and after the
self-administration session for a total of 10 samples. Two blood samples
were taken before the self-administration session (40 and 10 min).
Samples were taken during the session at the beginning of each time-out
component (25, 60, 95, and 130 min). Samples were also taken after the
session at 165, 200, 260, and 320 min.
Blood Collection and Handling. Each sample was placed in a 2-ml
Vacutainer (Becton Dickinson, Franklin Lakes, NJ) containing 0.04 ml of
7.5% ethylenediaminetetraacetic acid and immediately placed on ice.
After each sample was drawn, the catheter was flushed with approximately
3 ml of heparin saline (30 units/ml).
Blood samples were centrifuged at 4500 rpm for 5 min at 4°C. The
plasma was pipetted into 2-ml Cryovials (Corning Costar Corp., Cam-
bridge, MA) and stored at 80°C until assayed for plasma ACTH and
cortisol. The ACTH concentrations were measured by using commercially
available radioimmunoassay kits (Nichols Institute Diagnostics, San Juan
Capistrano, CA). The range of detection was 1 to 1500 pg/ml. The
intra-assay and interassay coefficients of variation were 3–3.2% and 6–8%,
respectively.
Data Analysis
The ACTH data are presented as time-course data (hormone concen-
trations at different time points throughout the session). The mean and
SEM were calculated. These data were analyzed with a two-way repeated-
measures ANOVA by using condition  time. For the data collected
during noncontingent ethanol administration, the initial analysis com-
pared the effects of saline and the three ethanol doses. This analysis was
made to determine whether ethanol alone increased ACTH levels. The
second analysis included the data collected when naltrexone was given in
addition to ethanol.
For the data collected during response-contingent ethanol administra-
tion, the initial analysis compared the effects of 0.03 g/kg per injection of
ethanol in the presence of intramuscular injections of saline and the four
naltrexone doses to determine whether naltrexone would alter the effects
of ethanol on ACTH levels. The second analysis included the effects of
intramuscular injections of saline and 0.3 mg/kg naltrexone when saline
was available for self-administration. When significant effects (p  0.05)
were found, a post hoc Tukey’s honestly significant difference test was
applied.
Least-squares linear regression analysis was performed on the ethanol
intake and the corresponding ACTH area under the curve (AUC) for
ethanol self-administration. The AUCs were calculated by using the trap-
ezoidal rule (Tallarida and Murray, 1987). The first sample collected (at
30 min for noncontingent ethanol and 40 min for response-contingent
ethanol) was used as the reference for the calculation of the AUC for
ACTH. The AUC was calculated for each subject and averaged across all
subjects for conditions in which ethanol was self-administered.
The number of injections and the ethanol intake were each analyzed by
using a one-way repeated-measures ANOVA followed by a post hoc
Tukey’s honestly significant difference test. Included in the analysis for the
number of injections were the data for ethanol self-administration after
intramuscular injections of saline and 0.01 to 0.3 mg/kg naltrexone.
Drugs
Ethanol 95% (Pharmco Products Inc., Brookfield, CT) was mixed with
0.9% saline. Naltrexone hydrochloride (provided by the NIDA Research
Technology Branch) was dissolved in sterile water.
RESULTS
Noncontingent intravenous administration of three doses
of ethanol resulted in a small, but statistically significant,
increase in plasma ACTH levels (Fig. 1, open symbols);
there was a main effect of ethanol [F(3,9)  4.32; p  0.05].
This effect was not related to the dose of ethanol. Average
ACTH levels after saline were 9 to 18 pg/ml; after 0.3, 1,
and 1.8 g/kg ethanol, ACTH levels peaked at an average of
31, 18, and 27 pg/ml, respectively. The effect was somewhat
delayed as well, peaking 2 hr after the intravenous infusion.
After the largest dose of ethanol (1.8 g/kg), the monkeys
showed signs of intoxication such as reduced locomotor
activity and ataxia.
Intramuscular injections of 0.32 mg/kg naltrexone produced
variable but substantially greater increases in ACTH levels
than did ethanol (Fig. 1, filled diamonds); there was a main
effect of naltrexone [F(5,15)  3.71; p  0.05]. Average
ACTH plasma levels were increased 30 min after naltrexone
administration and peaked 75 min after naltrexone adminis-
tration which are depicted as time 15 and time 60, respec-
tively, in Fig. 1. The ACTH levels were quite variable across
the subjects. For example, 60 min after naltrexone adminis-
tration, ACTH levels ranged from 10 to 545 pg/ml.
When intramuscular naltrexone (0.32 mg/kg) was admin-
istered before an intravenous bolus infusion of 1.8 g/kg
ethanol, ACTH levels over time were less than those pro-
duced by naltrexone alone. This difference was significant
at the 45- to 90-min measurements. This combination of
Fig. 1. ACTH levels (pg/ml) are plotted across time for four monkeys receiving
noncontingent infusions of saline or 0.3, 1.0, and 1.8 g/kg ethanol. Also shown is
the effect of treatment with intramuscular injection of 0.32 mg/kg naltrexone
before infusion with saline or 1.8 g/kg ethanol. The lined bar along the x axis
indicates the approximate infusion duration. All infusions began at 5 min. The
arrow at 15 min indicates the time of naltrexone injection. aSignificant difference
from saline infusion alone and all doses of ethanol alone at the same time points
(p  0.05); bsignificant difference from 1.8 g/kg ethanol with 0.32 mg/kg naltrex-
one at the same time points (p  0.05). Etoh, ethanol; NTX, naltrexone.
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naltrexone and 1.8 g/kg ethanol produced larger ACTH
levels than those produced by ethanol alone, and this dif-
ference was significant at all but the 120- and 180-min
measurement times (Fig. 1).
When 0.03 g/kg per injection of ethanol was made re-
sponse contingent, monkeys took an average of 62 injec-
tions (1.9 g/kg) during the session (Fig. 2). The monkeys
received significantly fewer injections (n  9) when
response-contingent saline was available [F(6,24)  8.07; p
 0.001]. The self-administered ethanol did not alter
ACTH levels (Fig. 3; closed circle with inserted cross)
during or after the session. The average cumulative ethanol
intake at the end of each of the four response components
was 0.88, 1.52, 1.81, and 1.9 g/kg; the average ACTH levels
were 4 to 14 pg/ml during these periods of ethanol self-
administration, which was not significantly different from
the ACTH levels of 5 to 12 pg/ml that were measured
during saline self-administration after a saline pretreat-
ment (Fig. 3; closed circles).
Pretreatment with intramuscular naltrexone 0.3 mg/kg
before the opportunity to self-administer saline increased
plasma ACTH (Fig. 3; closed diamonds). ACTH levels
increased gradually after the naltrexone administration
compared with the rate of increase after a bolus injection of
saline in the previous part of this study (refer to Fig. 1). The
peak values (119–148 pg/ml) developed between 130 and
260 min after naltrexone injection and were also lower than
those obtained previously.
Pretreatment with increasing doses of naltrexone resulted
in a dose-dependent decrease in number of ethanol injections
taken and ethanol intake (Fig. 2). The number of ethanol
injections was significantly decreased after administration of
0.03 to 0.3 mg/kg naltrexone [F(4,16)  5.81; p  0.005].
When ethanol self-administration followed naltrexone
administration, ACTH levels were greater than those pro-
duced by ethanol self-administration alone [main effect of
naltrexone: F(4,16)  5.65; p  0.005]. For example,
ACTH levels after ethanol with the two highest naltrexone
doses (Fig. 3; open triangles and inverted open triangles) at
various points between time 25 and 130 were greater than
the ACTH levels after ethanol with saline at the same time
points. However, the ACTH levels after all the ethanol/
naltrexone combinations were not statistically different
from one another. When the analysis included saline self-
administration after 0.3 mg/kg naltrexone (closed dia-
monds), the ACTH levels for this condition were signifi-
cantly higher than for all other manipulations from time
130 to the end of the sampling period [F(9,36)  7.76; p 
0.005]. When examined in the context of the saline self-
administration after 0.3 mg/kg naltrexone, the ethanol/sa-
line and ethanol/naltrexone combinations failed to produce
statistically significant effects. Thus, ethanol seemed to
dampen the ACTH-stimulating effect of 0.3 mg/kg naltrex-
one (Fig. 3; open inverted triangles).
Least-squares linear regression analysis was performed
on the ethanol intake and the corresponding ACTH AUC
when intramuscular saline or 0.01 to 0.3 mg/kg naltrexone
was given before ethanol self-administration (Fig. 4). The
slope of the regression line was significantly less than 0
[F(1,23)  23.7; p  0.001], indicating that ethanol intake
was negatively correlated with ACTH AUC. The resulting
regression equation was y  0.003x  1.51, and approx-
imately 51% of the variance in the data was accounted for
by the regression equation (R  0.71).
DISCUSSION
Intravenous ethanol administration, either noncontin-
gent or response contingent, did not result in marked in-
Fig. 2. The number of ethanol injections (open bars) and ethanol intake (g/kg;
F) are shown for five monkeys receiving response-contingent ethanol (0.03 g/kg
per injection) after pretreatment with intramuscular injections of saline or 0.01 to
0.3 mg/kg naltrexone. Response-contingent saline injections are depicted by the
lined bar. aSignificant difference for number of ethanol injections and ethanol
intake compared with those obtained with saline pretreatment (p  0.05). NTX,
naltrexone.
Fig. 3. ACTH levels (pg/ml) are plotted across time for five monkeys receiving
response-contingent saline or ethanol (0.03 g/kg per injection) after pretreatment
with intramuscular injections of saline or 0.01 to 0.3 mg/kg naltrexone. The lined
bar along the x axis indicates the duration of the self-administration session. The
arrow at 15 min indicates the time of naltrexone injection. aACTH levels were
significantly different from those when ethanol was self-administered after intra-
muscular saline (p  0.05); bACTH levels were significantly different from those
when ethanol was self-administered after any dose of naltrexone (p  0.05). Etoh,
ethanol; NTX, naltrexone; Sal, saline.
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creases in ACTH plasma levels. This result is in contrast to
most studies in rats and humans, in which ethanol has been
shown to stimulate the HPA axis (Inder et al., 1995; Mc-
Caul et al., 2001; Mendelson and Stein, 1966; Merry and
Marks, 1969; Rivier, 1996). One factor that may play a role
in ethanol’s inability to increase ACTH levels in our exper-
iments is the route of ethanol administration. Most reports
of ethanol’s HPA effects in humans involve oral consump-
tion of ethanol. Oral ethanol has a number of foodlike
qualities (e.g., gastric expansion, caloric value, and effects
on insulin), and both ACTH and cortisol levels increase in
humans after they have consumed a standardized meal
(Al-Damluji et al., 1987; Dodt et al., 1994). Route of ad-
ministration might also influence the ACTH increases that
have been observed after intraperitoneal administration of
ethanol to rats. Although various procedures have been
used to reduce the irritation that results from ethanol in the
peritoneum, it is possible that ethanol by the intraperito-
neal route may be an irritant.
Evaluation of the HPA axis effects of intravenously de-
livered ethanol in rats and other animals, as well as hu-
mans, would help to clarify this issue. The few studies that
have examined the effects of intravenous ethanol on HPA
activity in humans (Davis and Jeffcoate, 1983; Jenkins and
Connolly, 1968) found that cortisol increased only after
ethanol doses that increased blood ethanol levels to greater
than 100 mg/100 ml and caused illness or dysphoria. Only
one animal study was found that examined HPA activity
after intravenous ethanol administration. Cudd et al.
(1996) infused 0.5 to 2 g/kg ethanol intravenously into
sheep over 60 min. Ethanol increased ACTH levels, but the
effects were not dose related, and ACTH levels were as
high after only a saline injection.
In contrast to the finding that intravenous ethanol did
not increase ACTH levels, intramuscular naltrexone pro-
duced large increases of plasma ACTH. This result repli-
cates those from a study in which we examined the ability of
naltrexone and other opioid receptor-selective antagonists
to increase plasma ACTH and cortisol levels (Williams et
al., 2003). Although the magnitude of the HPA response to
naltrexone is larger and more variable in this experiment,
the effective doses and the HPA response pattern are
similar to those from the previous study. This finding also
agrees with the findings in humans that acute administra-
tion of various opioid antagonists increases HPA activity.
For example, intravenous naloxone and nalmefene increase
plasma ACTH and cortisol (Jackson et al., 1995; Schluger
et al., 1998; Wand et al., 1999). Oral naltrexone increases
plasma ACTH and cortisol (Farren et al., 1999; King et al.,
2002). However, there are interactive effects of ethanol and
naltrexone on the HPA axis. McCaul et al. (2001) demon-
strated that naltrexone blocked ethanol-induced activation
of the HPA axis even though naltrexone’s direct effects on
the HPA axis had long since disappeared (approximately 15
hr after naltrexone administration). O’Malley et al. (2002)
showed that naltrexone augmented ethanol’s effect on the
HPA axis despite blood sampling 6 hr after naltrexone, a
time when naltrexone’s direct effects on the HPA axis are
declining (Farren et al., 1999; King et al., 2002). These
human studies suggest that we may also observe an inter-
action between naltrexone and ethanol on ACTH levels. In
the current experiments, noncontingently delivered ethanol
attenuated naltrexone-induced increases in plasma ACTH.
Ethanol has been shown to impair HPA sensitivity to other
stimuli. For example, ethanol blocked the ACTH increase
stimulated by ovine corticotropin-releasing hormone
(Waltman et al., 1994). It is not clear how these different
HPA effects of naltrexone are related to the therapeutic
reduction of alcohol consumption observed clinically.
The magnitude and timing of naltrexone’s effect on
ACTH levels were different depending on the context in
which the infusions were given (i.e., noncontingent or
response-contingent ethanol/saline infusions). When nal-
trexone was given before a noncontingent infusion of sa-
line, ACTH levels increased within 30 min of the naltrex-
one injection. Peak ACTH levels of 255 pg/ml were reached
75 to 105 min after the injection, and these values had
decreased to prenaltrexone levels by 195 min after the
injection. This pattern of ACTH response to naltrexone
was similar to that found in a previous study in this labo-
ratory that used similar conditions (Williams et al., 2003).
When naltrexone was given before a session in which
response-contingent saline was available, peak ACTH in-
creases occurred more than 3 hr after the naltrexone injec-
tion, and the ACTH levels were still increased 5.5 hr after
the administration of naltrexone. The delayed and attenu-
ated ACTH response to naltrexone when response-
contingent saline was available might be due to learning
processes associated with the self-administration experi-
ence. All monkeys experienced naltrexone with response-
contingent saline after they had an extensive history of
ethanol self-administration in the presence of naltrexone. It
Fig. 4. Ethanol intake (g/kg) is plotted against the ACTH AUC (pg·ml/min).
Least-squares linear regression analysis was performed on these data (R2 
0.51). The regression line is also plotted.
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is possible that the experience of the attenuating effect of
ethanol on the ACTH-enhancing effect of naltrexone be-
came conditioned under these repeated exposures and that
it is this conditioned suppression that reduced the ability of
naltrexone to stimulate ACTH release when it was given
before saline self-administration.
It is interesting to note that the ACTH increases after 0.3
mg/kg naltrexone were quite modest when ethanol was
available after the injection, even though this dose of nal-
trexone reduced the amount of ethanol taken only to 0.32
g/kg on average. A part of this ethanol-induced attenuation
of naltrexone’s effects on ACTH levels may also have been
a conditioned effect.
This study indicates that the interaction of naltrexone
and ethanol on the HPA axis does not depend on whether
ethanol was self-administered or delivered by the experi-
menter; noncontingent ethanol was able to reduce
naltrexone-induced increases in plasma ACTH. Because
intravenous ethanol in the monkey did not increase these
hormones as oral ethanol does in humans, this study does
not effectively answer the question of whether naltrexone
dampens (McCaul et al., 2001) or enhances (O’Malley et
al., 2002) the HPA-stimulating effects of ethanol. However,
there was a strong negative correlation between ethanol
intake and ACTH plasma levels over time in the monkey,
similar to the negative correlation that was observed be-
tween cortisol levels and intensity of alcohol craving and
drinks taken by humans (O’Malley et al., 2002). In both this
study and that of O’Malley et al., high stress hormone levels
after ethanol consumption in the presence of naltrexone
may be related to the ability of naltrexone to suppress
ethanol drinking. Noncontingent ethanol administration
clearly suppressed naltrexone’s effect on ACTH levels, and
this same relationship may be applied to response-
contingent ethanol administration. Because naltrexone re-
duced ethanol self-administration, there was less ethanol
present to exert an inhibitory influence on naltrexone’s
ability to increase HPA activity.
ACKNOWLEDGMENTS
We thank Gail Winger for help with manuscript preparation
and Nick Jones and Partha Mukhopadhyay for technical
assistance.
REFERENCES
Al-Damluji S, Iveson T, Thomas JM, Pendlebury DJ, Rees LH, Besser
GM (1987) Food-induced cortisol secretion is mediated by central
alpha-1 adrenoreceptor modulation of pituitary ACTH secretion. Clin
Endocrinol 26:629–636.
Cudd TA, Chen WJ, West JR (1996) Acute hemodynamic, pituitary, and
adrenocortical responses to alcohol in adult female sheep. Alcohol Clin
Exp Res 20:1675–1681.
Davis JRE, Jeffcoate WJ (1983) Lack of effect of ethanol on plasma
cortisol in man. Clin Endocrinol 19:461–466.
Dodt C, Hansen K, Uthgenannt D, Born J, Fehm HL (1994) Cholinergic
potentiation of the meal-induced rise in ACTH and cortisol concentra-
tions in men. Exp Clin Endocrinol 102:460–466.
Farren CK, O’Malley S, Grebski G, Maniar S, Porter M, Kreek MJ (1999)
Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stim-
ulation in abstinent alcoholics: a preliminary study. Alcohol Clin Exp
Res 23:502–508.
Inder WJ, Joyce PR, Wells JE, Evans MJ, Ellis MJ, Mattioll L, Donald RA
(1995) The acute effects of oral ethanol on the hypothalamic-pituitary-
adrenal axis in normal human subjects. Clin Endocrinol 42:65–71.
Jackson RV, Grice JE, Hockings GI, Torpy DJ (1995) Naloxone-induced
ACTH release: mechanism of action in humans. Clin Endocrinol 43:
423–424.
Jenkins JS, Connolly J (1968) Adrenocortical response to ethanol in man.
Br Med J 2:804–805.
King AC, Schluger J, Gunduz M, Borg L, Perret G, Ho A, Kreek MJ
(2002) Hypothalamic-pituitary-adrenocortical (HPA) axis response and
biotransformation of oral naltrexone: preliminary examination of rela-
tionship to family history of alcoholism. Neuropsychopharmacology
26:778–788.
McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001) Naltrex-
one dampens ethanol-induced cardiovascular and hypothalamic-
pituitary-adrenal axis activation. Neuropsychopharmacology
25:537–547.
Mendelson JH, Mello NK, Cristofaro P, Skupny A, Ellingboe J (1986) Use
of naltrexone as a provocative test for hypothalamic-pituitary hormone
function. Pharmacol Biochem Behav 24:309–313.
Mendelson JH, Stein S (1966) Serum cortisol levels in alcoholic and
nonalcoholic subjects during experimentally induced ethanol intoxica-
tion. Psychosom Med 28:616–626.
Merry J, Marks V (1969) Plasma-hydrocortisone response to ethanol in
chronic alcoholics. Lancet 2:107–108.
National Research Council (1996) Guide for the Care and Use of Labora-
tory Animals. National Academy Press, Washington, DC.
O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek J (2002) Nal-
trexone decreases craving and alcohol self-administration in alcohol-
dependent subjects and activates the hypothalamo-pituitary-
adrenocortical axis. Psychopharmacology (Berl) 160:19–29.
Rivier C (1996) Alcohol stimulates ACTH secretion in the rat: mecha-
nisms of action and interactions with other stimuli. Alcohol Clin Exp
Res 20:240–254.
Schluger JH, Ho A, Borg L, Porter M, Maniar S, Gunduz M, Perret G,
King A, Kreek MJ (1998) Nalmefene causes greater hypothalamic
pituitary-adrenal axis activation than naloxone in normal volunteers:
implications for the treatment of alcoholism. Alcohol Clin Exp Res
22:1430–1436.
Tallarida RJ, Murray RB (1987) Manual of Pharmacologic Calculations
With Computer Programs. Springer, New York.
Waltman C, McCaul ME, Wand GS (1994) Adrenocorticotropin re-
sponses following administration of ethanol and ovine corticotropin-
releasing hormone in the sons of alcoholics and control subjects. Alco-
hol Clin Exp Res 18:826–830.
Wand G, McCaul ME, Gotjen D, Reynolds J, Lee S (2001) Confirmation
that offspring from families with alcohol-dependent individuals have
greater hypothalamic-pituitary-adrenal axis activation induced by nal-
oxone compared with offspring without a family history of alcohol
dependence. Alcohol Clin Exp Res 25:1134–1139.
Wand GS, Mangold D, Ali M (1999) Adrenocorticotropin responses to
naloxone in sons of alcohol-dependent men. J Clin Endocrinol Metab
84:64–68.
Williams KL, Holden Ko MC, Rice KC, Woods JH (2003) Effect of opioid
receptor antagonists on hypothalamic-pituitary-adrenal activity in rhe-
sus monkeys. Psychoneuroendocrinology 28:513–528.
Winger G, Stitzer ML, Woods JH (1975) Barbiturate-reinforced respond-
ing in rhesus monkeys: comparisons of drugs with different durations of
action. J Pharmacol Exp Ther 195:505–514.
NALTREXONE EFFECTS ON HPA ACTIVITY IN RHESUS MONKEYS 571
